CD274 and neoplasm: Anti-PD-L1 immunotherapy (200 mg of pembrolizumab in the cohort 1 and 350 mg of cemiplimab in the cohort 2) will be administered in addition to ASP-1929 to assess the safety, tolerability and tumour response of this combined regimen.